Cubist Acquires Illumigen Biosciences | Chemical & Engineering News
Volume 86 Issue 1 | p. 12 | Concentrates
Issue Date: January 7, 2008

Cubist Acquires Illumigen Biosciences

Department: Business

Cubist Pharmaceuticals has acquired Illumigen Biosciences, which specializes in the use of human genetic mutations in drug discovery and development. Illumigen's lead compound, IB657, is in preclinical development for the treatment of hepatitis C virus (HCV) infection. Under the deal, Cubist will pay $9 million to establish Illumigen as a subsidiary and will pay Illumigen's former owners up to $75.5 million upon reaching regulatory milestones. Cubist could pay up to $117 million for the development of products that treat viruses other than HCV. Cubist CEO Mike Bonney says the firm hopes to make an investigational new drug filing for IB657 and begin clinical trials this year.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment